Blood Markers Predict CAR T-cell Therapy Side Effects
A study published September 25, 2026, links baseline B-cell counts and IL-6 levels to cytokine release syndrome risk.
Updated on Oct. 23, 2026 in Arthritis
Live Poll
Is it worth undergoing additional blood testing to predict potential side effects before starting new treatments?
Researchers have identified baseline blood markers that correlate with the risk of cytokine release syndrome in patients undergoing CAR T-cell therapy. The retrospective study published on September 25, 2026, analyzed data from 108 patients across seven medical centers.
Why it matters
Identifying these predictive markers could help clinicians better manage treatment risks for patients receiving autologous CAR T-cell therapy. The findings offer a potential diagnostic tool for anticipating adverse immune responses before they occur.
In the study of 108 patients, 80% experienced cytokine release syndrome, including 66% with Grade 1 severity. Researchers identified B-cell counts of 25.66 cells/µL and IL-6 concentrations of 6.82 pg/mL as cutoffs for higher-risk groups.
The players
The Lancet Rheumatology
This peer-reviewed medical journal published the study and serves as a major platform for disseminating rheumatology research internationally.
The details
The analysis assessed levels of B-cell counts, IL-6, ferritin, and C-reactive protein prior to the initiation of therapy to identify risk profiles. While cytokine release syndrome was common, immune effector cell-associated neurotoxicity syndrome occurred in only 3% of the study population.
Timeline
The study patient enrollment period began in March 2021.
The study patient enrollment period concluded in July 2025.
The findings were published online on September 25, 2026.
Health Landscape
This research advances the safety protocols for the clinical application of CAR T-cell therapy for autoimmune disease by refining patient risk assessment. It marks a shift toward predictive monitoring that could reduce the incidence of severe complications during treatment.
Patients preparing for CAR T-cell therapy may benefit from enhanced screening protocols that identify their risk level for cytokine release syndrome before treatment begins. This proactive approach could allow medical teams to prepare appropriate interventions earlier in the process.
The takeaway
Understanding biological markers before treatment enables a more personalized approach to managing complex autoimmune therapies. Clinicians may incorporate these findings to monitor high-risk patients more closely throughout their recovery phase.
Further reading
For more information on current treatment trends, visit the Arthritis section.
Source note: This article includes information reported by Medscape.
Live Poll
Is it worth undergoing additional blood testing to predict potential side effects before starting new treatments?
